Skip to main content
. 2010 Aug 10;103(5):656–662. doi: 10.1038/sj.bjc.6605817

Table 3. Genes found to correlate in multivariate linear regression analysis.

Model R R 2 Adj R2 Std. error Significance (ANOVA)
(A)
Cisplatin 0.949 0.901 0.836 35.226 P<0.001
Doxorubicin 0.797 0.636 0.524 98.669 P<0.007
Gemcitabine 0.766 0.586 0.524 88.312 P<0.001
Paclitaxel 0.848 0.720 0.646 78.669 P<0.001
Topotecan 0.900 0.811 0.751 60.457 P<0.001
Treosulfan 0.994 0.989 0.977 10.769 P<0.001
Cisplatin+Gemcitabine 0.899 0.807 0.743 63.769 P<0.001
Treosulfan+Gemcitabine 0.904 0.817 0.753 33.823 P<0.001
             
  Unstandardized
    Collinearity statistics
Gene B Std. Error Standardized β t Lower bound B Std. error
(B)            
Cisplatin
 (Constant) 489.826 22.739   21.541    
Rad51 −41.140 6.003 −0.801 −6.853 0.482 2.077
IGF1R −61.361 11.034 −0.737 −5.561 0.375 2.668
p53 19.690 8.267 0.217 2.382 0.792 1.263
Topo I 43.796 9.300 0.522 4.709 0.534 1.872
MRP5 17.255 5.629 0.345 3.065 0.518 1.929
Survivin −11.745 4.880 −0.286 −2.407 0.466 2.145
HSP60 42.165 9.610 0.491 4.388 0.526 1.901
BCRP −21.628 5.093 −0.632 −4.247 0.297 3.368
Mcl-1 16.918 6.486 0.252 2.609 0.707 1.414
 Ki67 11.667 5.487 0.259 2.126 0.442 2.264
             
Doxorubicin
 (Constant) 69.454 125.422   0.554    
GST pi 106.938 31.844 0.649 3.358 0.751 1.332
MRP4 80.498 25.470 0.585 3.161 0.817 1.225
MRP5 −36.958 13.921 −0.500 −2.655 0.790 1.266
Topo IIa −14.009 16.405 −0.164 −0.854 0.759 1.318
             
Gemcitabine
 (Constant) 407.883 28.640   14.242    
 (Constant) 454.312 37.512   12.111    
MCJ −46.173 10.778 −0.621 −4.284 0.983 1.018
XRCC1 52.043 14.788 0.571 3.519 0.785 1.274
XPA −48.982 19.639 −0.402 −2.494 0.797 1.255
             
Paclitaxel
 (Constant) 343.514 37.244   9.223    
Survivin −42.179 8.466 −0.675 −4.982 0.804 1.245
IGF2R 109.226 18.578 1.122 5.879 0.405 2.472
Mcl-1 −70.805 17.654 −0.799 −4.011 0.372 2.689
GCLM 40.381 12.968 0.490 3.114 0.596 1.677
TAP2 −36.754 15.467 −0.333 −2.376 0.750 1.333
             
Topotecan
 (Constant) 356.986 30.510   11.701    
APAF1 75.074 11.458 0.805 6.552 0.785 1.274
SDHA −42.701 9.085 −0.578 −4.700 0.783 1.277
HER2 −41.223 8.955 −0.618 −4.604 0.657 1.521
MRP4 55.124 15.928 0.510 3.461 0.546 1.831
IGF2R 36.298 15.445 0.355 2.350 0.520 1.924
             
Treosulfan
 (Constant) −46.200 22.925   −2.015    
MLH1 42.868 1.922 0.893 22.304 0.646 1.549
Bax 75.608 5.919 0.927 12.774 0.197 5.083
Bcl2 −31.437 1.650 −1.244 −19.054 0.243 4.115
p21 −69.282 3.493 −1.218 −19.837 0.275 3.641
GST pi 106.821 6.921 1.176 15.433 0.178 5.608
Ki67 −17.337 1.649 −0.509 −10.511 0.441 2.266
APC N-term 56.943 5.738 0.870 9.924 0.135 7.417
HIF1A −45.059 6.890 −0.566 −6.539 0.138 7.224
p16 7.875 1.539 0.208 5.117 0.629 1.589
Survivin −7.258 1.554 −0.223 −4.671 0.455 2.198
Bid −15.379 4.423 −0.204 −3.477 0.301 3.327
             
Cisplatin+Gemcitabine
 (Constant) −195.787 106.134   −1.845    
FPGS 58.087 11.147 0.630 5.211 0.733 1.364
IGFBP2 −27.128 11.555 −0.275 −2.348 0.778 1.285
MDR1 −52.072 8.573 −0.871 −6.074 0.520 1.922
18s 48.716 11.831 0.578 4.118 0.543 1.841
XRCC5 144.209 32.907 0.859 4.382 0.278 3.591
HIF1A −76.886 25.948 −0.555 −2.963 0.305 3.281
             
Treosulfan+gemcitabine
 (Constant) 280.890 22.522   12.472    
ATP7B −25.392 4.143 −0.721 −6.128 0.776 1.289
Bad 27.786 8.089 0.401 3.435 0.787 1.271
MTII −55.067 10.870 −0.648 −5.066 0.657 1.521
p53 34.839 8.973 0.485 3.883 0.690 1.449
IGF2 −12.457 3.713 −0.391 −3.355 0.791 1.265
GCLM 11.706 4.972 0.272 2.354 0.807 1.239

Abbreviation: ANOVA=analysis of variance.

(A) With ATP-TCA data for recurrent ovarian cancer: model summaries; (B) using forward selection: coefficients for each gene included in the model by drug or combination tested.